Summary

Market Size & Trends

The U.S. hereditary cancer testing market was estimated at USD 1.93 billion in 2024 and is projected to reach USD 5.76 billion by 2033, growing at a CAGR of 13.32% from 2025 to 2033. The U.S. hereditary cancer testing market is driven by growing awareness of inherited cancer risks, with 5-10% of cancers linked to germline mutations. Rising adoption of guideline-based screening from NCCN and ACOG, coupled with FDA authorization of panels, is boosting clinician confidence and payer coverage. Technological advancements such as integration of DNA/RNA sequencing, digital screening tools, and combined germline-somatic profiling are expanding clinical utility. Increasing partnerships, patient education initiatives, and insurance support are further accelerating access, positioning hereditary testing as a cornerstone of precision oncology.

In the United States, between five and ten percent of all cancers are associated with inherited mutations in cancer predisposition genes. These hereditary mutations, passed down through families, increase the risk of developing cancers such as breast, ovarian, colorectal, prostate, and others. While most of the estimated 270,000 annual breast cancer cases among women, 2,000 among men, and 20,000 ovarian cancer cases occur sporadically, a notable proportion is hereditary. This underscores the importance of genetic testing as a tool for both early detection and preventive healthcare. The National Comprehensive Cancer Network (NCCN) has established guidelines to identify individuals most likely to carry mutations, primarily based on personal and family cancer histories. Yet, despite the strength of these guidelines, hereditary testing has historically been underutilized, partly because of inconsistent interpretation across laboratories and limited patient access.

U.S. Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the hereditary cancer testing market report on the basis of test type, technology, cancer, andend-use:
• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Ovarian Cancer
• Prostate Cancer
• Stomach/Gastric Cancer
• Melanoma
• Sarcoma
• Uterine Cancer
• Pancreatic Cancer
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cytogenetic
• Biochemical
• Molecular Testing
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Predictive Testing
• Diagnostic Testing
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Centers
• Hospitals
• Clinics

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Cancer
1.2.2. Technology
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Cancer outlook
2.2.2. Technology outlook
2.2.3. Test Type outlook
2.2.4. End Use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. U.S. Hereditary Cancer Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Technological advancements of genetic testing in cancer detection
3.2.1.2. Integration with precision medicine
3.2.1.3. Growing awareness through public and government initiatives
3.2.1.4. Rising prevalence of cancer
3.2.2. Market restraint analysis
3.2.2.1. High costs and limited insurance coverage
3.3. U.S. Hereditary Cancer Testing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
Chapter 4. U.S. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Hereditary Cancer Testing Market: Cancer Movement Analysis
4.3. U.S. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
4.4. U.S. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Lung Cancer
4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Breast Cancer
4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Colorectal Cancer
4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.8. Cervical Cancer
4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.9. Ovarian Cancer
4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.10. Prostate Cancer
4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.11. Stomach/Gastric Cancer
4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.12. Melanoma
4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
4.13. Sarcoma
4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
4.14. Uterine Cancer
4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.15. Pancreatic Cancer
4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
4.16. Others
4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis
5.1. Technology Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. U.S. Hereditary Cancer Testing Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Cytogenetic
5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Biochemical
5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Molecular Testing
5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis
6.1. Test type Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Test type Market by Capacity Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Predictive Testing
6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Diagnostic Testing
6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. U.S. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis
7.1. End Use Market Share, 2024 & 2033
7.2. Segment Dashboard
7.3. End Use Market by End Use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.5. Diagnostic Centers
7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Hospitals
7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Clinics
7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Myriad Genetics, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Services benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Invitae Corporation
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Services benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Bio-Rad Laboratories
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Services benchmarking
8.3.6.4. Strategic initiatives
8.3.7. CSL Ltd
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Services benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Qiagen NV
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Services benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Danaher Corporation
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Services benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Thermo Fisher Scientific
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Services benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Abbott Laboratories
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Services benchmarking
8.3.11.4. Strategic initiatives
8.3.12. EUROFINS SCIENTIFIC
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Services benchmarking
8.3.12.4. Strategic initiatives
8.3.13. F. HOFFMANN-LA ROCHE LTD
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Services benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Illumina, Inc.
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Services benchmarking
8.3.14.4. Strategic initiatives